Based in NovaUCD, Biosensia is a point of care in vitro diagnostics company that has a novel point of care platform.   They have recently secured funding of €1.2million.  The funding, led by ACT Venture Capital, through its AIB Start-up Accelerator Fund will be used to secure CE mark and FDA regulatory approval for Biosensia’s products in Europe and the US and advance its commercial partnership strategy.  Biosensia have plans to increase staff numbers from 5 to 15 by 2013 as part of its commercialisation strategy.
IEA Life Sciences Ireland welcomes this announcement relating to another knowledge based life sciences start-up venture and wishes the company well as its commercialisation strategy proceeds.